<p>CF PharmTech, Inc. 宣布已向中国证券监督管理委员会（CSRC）提交了 H 股全流通的申请。该提案涉及将 107,408,422 股国内未上市股份按一对一的比例转换为 H 股，完成所有必要的备案、审批及遵守相关法规后，将在香港证券交易所上市交易。公司尚未向香港证券交易所申请转换和上市，实施计划的细节尚未最终确定。随着进展的取得，将会发布进一步的公告。免责声明：本新闻简报由公共技术（PUBT）使用生成性人工智能创建。尽管 PUBT 努力提供准确及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。CF Pharmtech Inc. 于 2026 年 1 月 12 日通过香港证券交易所（HKex）运营的发行人信息服务（IIS）发布了用于生成本新闻简报的原始内容（参考 ID：HKEX-EPS-20260112-11988263），并对此信息的内容承担全部责任。© 版权 2026 - 公共技术（PUBT）</p>

长风药业

<p>CF PharmTech, Inc. 已向中国证券监督管理委员会（CSRC）提交了 H 股全流通的申请，将 107,408,422 股国内未上市股份按一对一的比例转换为 H 股。一旦获得批准，这些股份将于香港证券交易所上市。该公司尚未申请转换和上市，后续将根据进展发布进一步公告</p>

<p>CF PharmTech, Inc. announced that it has submitted a filing application to the China Securities Regulatory Commission (CSRC) for the proposed implementation of H Share Full Circulation. The proposal involves the conversion of 107,408,422 domestic unlisted shares into H Shares on a one-for-one basis, which, upon completion of all required filings, approvals, and compliance with relevant regulations, will be listed and traded on the Hong Kong Stock Exchange. The company has not yet applied to the Hong Kong Stock Exchange for the conversion and listing, and the implementation plan details have not been finalized. Further announcements will be made as progress is achieved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260112-11988263), on January 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>CF PharmTech, Inc. 宣布已向中国证券监督管理委员会（CSRC）提交了 H 股全流通的申请。该提案涉及将 107,408,422 股国内未上市股份按一对一的比例转换为 H 股，完成所有必要的备案、审批及遵守相关法规后，将在香港证券交易所上市交易。公司尚未向香港证券交易所申请转换和上市，实施计划的细节尚未最终确定。随着进展的取得，将会发布进一步的公告。免责声明：本新闻简报由公共技术（PUBT）使用生成性人工智能创建。尽管 PUBT 努力提供准确及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。CF Pharmtech Inc. 于 2026 年 1 月 12 日通过香港证券交易所（HKex）运营的发行人信息服务（IIS）发布了用于生成本新闻简报的原始内容（参考 ID：HKEX-EPS-20260112-11988263），并对此信息的内容承担全部责任。© 版权 2026 - 公共技术（PUBT）</p>
</div>

长风药业已向中国证监会提交 H 股全流通申请